2024 International Congress Archives - Page 9 of 181

Obsessive-Compulsive Disorder Prevalence in Parkinson’s Disease Caregivers

F. Hojjatipour, M. Salari (tehran, Islamic Republic of Iran)
Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit

P. Ponger, G. Gurevich, R. Alcalay, Y. Bonneh, S. Shani (Tel Aviv, Israel)
Odor-specific symptoms in Parkinson’s disease – UPSIT odor identification status versus clinical severity.

YG. Guo, SC. Chiu (Taichung, Taiwan)
Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study

S. Markova, M. Baladi, M. Lee, C. Chen (Palo Alto, USA)
One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)
One-year longitudinal decline in spatial location memory in Huntington’s disease

M. Lunven, P. Vanden Enden, Y. Youssov, B. Bapst, G. Morgado, M. Busse, D. Craufurd, A. Rosser, AC. Bachoud-Lévi (Créteil, France)
One-Year Outcomes of Multitarget Thalamic and Pallidal Deep Brain Stimulation in Unilateral Dystonia

J. Altamirano, K. Salinas-Barboza, A. Armas-Salazar (Mexico City, Mexico)
Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON

J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, G. Castilla-Fernández, J. Rocha, J. Holenz, W. Poewe (Lisbon, Portugal)
Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease

J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)
Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease

J. Ferreira, J. Lee, H. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonesca, J. Rocha, G. Castilla-Fernández, J. Holenz, O. Rascol (Lisbon, Portugal)
Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial

J. Ferreira, M. Gago, R. Costa, M. Fonesca, J. Almeida, J. Rocha, J. Holenz, C. Trenkwalder (Lisbon, Portugal)
Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)
Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion

M. Minar, I. Straka, Z. Kosutzka, Z. Andre (Bratislava, Slovakia)
Opportunities for Medical Knowledge Self-Assessment in Movement Disorder Fellowship

A. Higinbotham, A. Wang, A. Toth, C. Kilbane (Charlottesville, USA)
Opsoclonus after Covid-19 infection

F. Sakeff, A. Vilar (São Paulo, Brazil)
Optical Coherence Tomography Findings in Multiple System Atrophy: Insights into Disease Subtypes, Clinical Correlations, and Dopaminergic Degeneration

Y. Kang (Hangzhou, China)
Optimal measuring height and validation of 2D-LiDAR based analysis system for spatiotemporal gait parameters

S. Woo, C. Shin, MY. Kim (Daegu, Republic of Korea)
OPTN gene associated with corticobasal syndrome: a novel multi-exon deletion and literature review

G. Bonato, M. Ginevrino, B. Savini, D. Ciprietti, P. Santurelli, E. Gasparoli, C. Gabelli, G. Sorarù, R. Biundo, M. Carecchio, A. Guerra, L. Salviati, A. Antonini (Padova, Italy)
Optogenetic Deep Brain Stimulation Rescues Motor Behavior in a Rat Model of Mild Parkinson’s Disease

A. Kirby, R. Romay-Tallon, A. Brown, C. Gonzalez, TC. Napier (Chicago, USA)
Oral health in Parkinson’s disease patients from countries with different economies: preliminary results of the OralPark study.

S. Rota, L. Batzu, A. Biondi, I. Boura, D. Urso, S. Diaconu, Y. Lau, I. Inês, P. Tall, P. Lyra, S. Puspasari, S. Gilani, P. Zinzalias, L. Neumaier, P. Pablo, C. Santoro, S. Landolfo, K. Popławska-Domaszewicz, C. Spanaki, P. Odin, DK. Sreenivas, LK. Prashanth, C. Falup-Pecurariu, A. Rizos, J. Botelho, KR. Chaudhuri (UK, United Kingdom)
ORION: A Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009)

A-M. Wills, G. Höglinger, L. Mehta, M. Leinders, Y. Wu, J. Timmons, A. Hayden, I. Aiba, A. Antonini, A. Boxer, Y. Compta, J-C. Corvol, A. Lang, H. Morris, P. Svenningsson, H. [email protected], L. Golbe (Boston, USA)
Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine

S. Saaf, S. Lhassani, Z. El Yacoubi, Y. Mimouni, M. El Azhari, L. Kazzoul, J. Aasfara, H. Ouhabi, A. Hazim (Casablanca, Morocco)
Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss

S. Jha (Kolkata, India)
Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film

L. Wojtecki, F. Moreira, E. Cubo, M. Fonseca, G. Harrison-Jones, C. Denecke Muhr (Düsseldorf, Germany)
Orthostatic hypotension in age-related neurodegenerative diseases: a bibliometric study from 2007 to 2023

Y. Qu, B. Zhang, C. Xing, Y. Yuan (Xi'an, China)
Orthostatic Hypotension is Associated with Worse Verbal Letter Fluency and Lower Neural Efficiency While Upright in Parkinson’s Disease: A Pilot Study

K. Longardner, P. Reddy, K. Izzetoglu, I. Litvan (SAN DIEGO, USA)
Orthostatic Hypotension：a Clinical Marker for the Body-First Subtype of Patients with Parkinson’s Disease

S. Mei, X. Wang, C. Han, P. Chan (Beijing, China)
Oscillatory network mapping of deep brain stimulation outcomes in Parkinson’s disease

B. Bahners, M. Sure, L. Goede, K. Butenko, C. Hartmann, J. Hirschmann, J. Vesper, T. Sander, GH. Schneider, A. Schnitzler, A. Kühn, E. Florin, A. Horn (Boston, USA)
Oscillatory signatures of genetic Parkinson’s disease patients in subthalamic macroelectrode recordings

N. Darcy, J. Habets, L. Feldmann, V. Mathiopoulou, JK. Behnke, J. Busch, J. Reimer, P. Krause, M. Gerster, B. Bahners, A. Schnitzler, GH. Schneider, K. Faust, A. Kühn (Berlin, Germany)
Outcomes in Patients with Parkinsonism Treated for Acute Agitation with Intravenous Benzodiazepines Compared to Parenteral Antipsychotics While Inpatient

A. Kundrick, C. Piccinin, J. Yu, P. Clark, S. Shaffer, O. Hogue, C. Sonneborn, B. Sokola, S. Sperling, H. Fernandez, B. Walter (Cleveland, USA)
Outpatient Treatment of Functional Movement Disorders

D. Hinkle, S. Patel, A. Husted, B. Darrah, B. Bettonville, C. Sabbagh (Columbus, USA)
Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)